Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | SLC12A5 | Q9H2X9 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3435935 | 0.78 | L3MBTL1 (0.37) | GRM5MEN1KMT2A | |
| SCHEMBL18674691 | 0.73 | ALDH1A1 (0.35) | GRM5LMNANOS1SMN1; SMN2MEN1 | |
| SCHEMBL232983 | 0.73 | SMN1; SMN2 (0.40) | LMNANOS1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10278352 | 0.71 | THRB (0.38) | GRM5LMNANOS1SMN1; SMN2MEN1 | |
| SCHEMBL3553091 | 0.71 | THRB (0.38) | GRM5LMNANOS1SMN1; SMN2MEN1 | |
| SCHEMBL13634342 | 0.70 | NOS1 (0.38) | LMNANOS1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL25933244 | 0.70 | SMN1; SMN2 (0.38) | LMNANOS1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3506347 | 0.69 | MAPK1 (0.42) | LMNANOS1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL770846 | 0.68 | — | — | |
| SCHEMBL3556009 | 0.67 | NOS1 (0.34) | LMNANOS1SMN1; SMN2KMT2ASLC12A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | GRM5 1055/4885LMNA 4712/4885NOS1 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.